Latest Deals

Silk Road’s product line consists of its ENROUTE range, including a neuroprotective system, stent system and balloon dilatation catheter, among others. Credit: Michael Vi / Shutterstock

Boston Scientific has agreed to acquire Silk Road Medical for around $1.26bn, adding the US-based carotid artery device specialist to its roster. Boston Scientific will pay $27.50 in cash per share of Silk Road, around a 38% premium to the latter’s volume-weighted average share price in the past 60 days. The deal represents a premium of 27% to the stock at the last market close.

BillionToOne, a molecular diagnostics company, has secured $130m in a Series D funding round to expand and scale its prenatal screening and oncology diagnostics businesses. BillionToOne’s QCTs technology has been pivotal in developing its diagnostic tests. To date, more than 500,000 patients have benefitted from BillionToOne’s offerings, which have propelled the company to $125m in annual recurring revenue in approximately four years.

In one of the biggest Series A funding rounds for a medtech company in Europe, UK-based Amber Therapeutics has raised $100m (£80m) to advance its implantable neuromodulation therapy for women with mixed urinary incontinence (MUI). Amber’s lead asset is Amber-UI, a fully implantable device targeting the treatment of MUI in women. The round was led by New Enterprise Associates (NEA). 

Osteal Therapeutics has raised $50m in a Series D financing round led by medtech giant Zimmer Biomet. The funds, which follow $23m raised in Series C financing in late 2023, will be used for a new drug application (NDA) to the US Food and Drug Administration (FDA) for VT-X7 and go towards advancing the US-based company’s musculoskeletal portfolio.